// App-Quantinova.ai

TPS4578 : Hcrn GU14-188: neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC).

Researchers

Presenter

  • Christopher J. Hoimes

Principal Investigators

  • Robert Abouassaly

  • Joel N. Saltzman

  • Mark T. Fleming

  • Jean H. Hoffman-Censits

  • Tara Byrd

  • Cheryl Eitman

  • Michele Snyder-Willis

  • Jodi O'Neill

  • Lisa Wood

  • Robin Elliott

  • Matthew M. Cooney

Medical Centers

  • Case Comprehensive Cancer Center at Seidman Cancer Center, Cleveland, OH

  • University Hospitals Case Medical Center, Cleveland, OH

  • University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

  • US Oncology Research, Virginia Oncology Associates, Hampton, VA

  • The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

  • Seidman Cancer Center at Lake, Cleveland, OH

  • Hoosier Cancer Research Network, Indianapolis, IN

  • Dept of Pathology, UH-Case Medical Center, Cleveland, OH

  • University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Gemcitabine

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02365766

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved